^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19 inhibitor

    Related drugs:
    19d
    Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL (clinicaltrials.gov)
    P1, N=60, Recruiting, Liping Dou
    New P1 trial
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    KMT2A rearrangement
    |
    Blincyto (blinatumomab)
    20d
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PIT565
    20d
    An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PIT565
    24d
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • KN5501
    24d
    BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia (ACTRN12617000084381)
    P2, N=30, Completed, Australasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed
    Trial completion
    |
    CD19 positive
    |
    cytarabine • Blincyto (blinatumomab) • methotrexate
    25d
    SOUNDTRACK-B: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (clinicaltrials.gov)
    P2, N=270, Recruiting, AstraZeneca | Trial completion date: Jun 2029 --> Oct 2032 | Trial primary completion date: Mar 2027 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    surovatamig (AZD0486)
    27d
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: May 2026 --> Nov 2026
    Trial initiation date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    Revuforj (revumenib)
    27d
    A single-center retrospective study of short-term efficacy and safety of blinatumomab in the treatment of high-risk acute lymphoblastic leukemia. (PubMed, BMC Cancer)
    Blinatumomab achieved high short-term MRD response rates in high-risk B-ALL. Inferior outcomes appeared to be associated with the presence of BCR::ABL1 T315I mutations and E2A::PBX1 rearrangements.
    Retrospective data • Journal
    |
    ABL1 (ABL proto-oncogene 1) • PBX1 (PBX Homeobox 1)
    |
    ABL1 T315I
    |
    Blincyto (blinatumomab)
    27d
    A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2030 --> Apr 2031 | Trial primary completion date: Jan 2030 --> Jul 2030
    Trial completion date • Trial primary completion date
    27d
    Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Jan 2027
    Enrollment closed • Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Zynyz (retifanlimab-dlwr) • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    27d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    28d
    AAAV0505: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=6, Enrolling by invitation, Hospital for Special Surgery, New York | Suspended --> Enrolling by invitation
    Enrollment open
    |
    cyclophosphamide • NKX019